DNTH — Dianthus Therapeutics, Inc. stock price, charts and financials

QT62Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
109.81
+0.89+0.82%
OverviewShort InterestFilings
DNTHQT62Dianthus Therapeutics, Inc.·NASDAQ
109.81+0.82%
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
CELC-0.13%$92.66EWTX+0.67%$43.81MANE-4.76%$108.94ELVN-0.90%$59.91PRTC+4.51%$17.38DYN+0.88%$26.48ACAD+1.20%$29.56DFTX-3.10%$44.71
Snapshot
Index-P/E-EPS (ttm)-2.88Insider Own18.92%Shs Outstand41.75MPerf Week1.87%
Market Cap4.55BForward P/E-EPS next Y-4.63Insider Trans-7.67%Shs Float29.16MPerf Month8.89%
Enterprise Value4.44BPEG138.32EPS next Q-Inst Own-Short Float31.62%Perf Quarter27.44%
Income-22.28MP/S-EPS this Y-32.14%Inst Trans-Short Ratio9.91Perf Half Y133.83%
Sales1.90MP/B5.21EPS next Y-21.60%ROA-2.47%Short Interest9.22MPerf YTD164.30%
Book/sh-P/C-EPS next 5Y-ROE-3.51%52W High115.48 -4.91%Perf Year434.18%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-18.47%52W Low18.23 502.43%Perf 3Y743.69%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-30.66% -Gross Margin96.01%Volatility4.97% 5.89%Perf 5Y-4.39%
Dividend TTM-EV/Sales-EPS Y/Y TTM-12.94%Oper. Margin-11441.39%ATR (14)6.00Perf 10Y-
Dividend Ex-Date-Quick Ratio26.10Sales Y/Y TTM0.00%Profit Margin-1570.85%RSI (14)57.77Recom1.91
Dividend Gr. 3/5Y-Current Ratio26.10EPS Q/Q-3.66%SMA203.91%Beta1.21Target Price124.18
Payout0.00%Debt/Eq0.00Sales Q/Q-100.00%SMA5014.83%Rel Volume0.56Prev Close108.92
Employees92LT Debt/Eq0.00EarningsNov 04SMA20059.04%Avg Volume1.03MPrice109.81
IPO DateJun 21, 2018Option/ShortYes / YesEPS/Sales Surpr.20.70% 14.71%Net Debt/EBITDA3.70Volume570,177Change0.82%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-06-26ReiteratedHC Wainwright & Co.Buy$130 → $158
Aug-05-26ReiteratedRaymond JamesStrong Buy$125 → $131
Aug-05-26ReiteratedWedbushOutperform$55 → $122
Jun-10-26ReiteratedJefferiesBuy$110 → $132
May-11-26ReiteratedEvercore ISI$122 → $120
May-06-26ReiteratedRaymond JamesStrong Buy$123 → $125
Apr-08-26InitiatedWolfe ResearchOutperform$98
Mar-10-26UpgradeRaymond JamesOutperform → Strong Buy
Mar-09-26ReiteratedUBS$81 → $98
Mar-09-26ReiteratedJefferiesBuy$51 → $98
Latest News
Aug-06-26
Aug-06-2604:03AM
Dimensional Fund Advisors LP Purchases 114,767 Shares of Dianthus Therapeutics, Inc. $DNTHdefenseworld.net
Aug-04-26
Aug-04-2606:41PM
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimateszacks.com
04:01PM
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Resultsglobenewswire.com
07:00AM
Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseasesglobenewswire.com
Aug-03-26
Aug-03-2606:00PM
Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)globenewswire.com
11:03AM
Evercore ISI Group Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $134Benzinga
Jul-02-26
Jul-02-2604:01PM
Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)globenewswire.com
Jun-29-26
Jun-29-2607:00AM
Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravisglobenewswire.com
Jun-12-26
Jun-12-2601:20PM
Why Is Dianthus Therapeutics Stock Trading Higher On Friday?Benzinga
Jun-11-26
Jun-11-2610:13AM
Dianthus Therapeutics: Sanofi's CIPD Study Fail Poses Uncomfortable QuestionsSeekingAlpha
09:09AM
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst SaysBenzinga
Jun-10-26
Jun-10-2608:05AM
12 Health Care Stocks Moving In Wednesday's Pre-Market SessionBenzinga
Company

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue626——————
Cost of Goods Sold Incl. D&A
000——————
Gross Profit626——————
Selling, General and Administrative Excl. Other273425——————
Research and Development9714683——————
Other Operating Expense
-100——————
Operating Income-117-178-102——————
Interest Expense
000——————
Unusual Expense
—————————
Non-Operating Income (Expense)171617——————
Net Income Before Taxes-101-162-85——————
Income Taxes
000——————
Consolidated Net Income-101-162-85——————
Net Income From Continuing Operations-101-162-85——————
Net Income-101-162-85——————
EPS (Recurring)-2.88-4.20-2.55——————
EPS (Basic, Before Extraordinaries)-2.88-4.20-2.55——————
EPS (Diluted)-2.88-4.20-2.55——————
EBITDA-99-162-85——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio658.86782.99119.90——————
Gross Margin100.00100.00100.00——————
Operating Margin-1,950.00-8,900.00-1,700.00——————
Net Margin-1,683.33-8,100.00-1,416.67——————
Shares Outstanding363833——————
Market Capitalization3,9531,566719——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$127.01$95.88$64.75$33.62$2.49● Close Price0.00M7.01M14.01M21.02M28.03MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Garcia MarinoCEO AND PRESIDENTAug 07 '26Sale108.11166,00017,945,45065,292Aug 07
Garcia MarinoCEO AND PRESIDENTAug 07 '26Option Exercise8.44166,0001,401,040231,292Aug 07
Savitz RyanEVP, CFO & CBOJul 09 '26Option Exercise21.7731,249680,29131,249Jul 13
Savitz RyanEVP, CFO & CBOJul 09 '26Sale101.0331,2493,157,1510Jul 13
Veness Adam MSVP, General Counsel and Sec.Jun 17 '26Option Exercise17.8830,000536,40030,000Jun 18
Veness Adam MSVP, General Counsel and Sec.Jun 17 '26Sale80.8030,0002,423,9580Jun 18
Randhawa SimratEVP, Head of R&DJun 01 '26Option Exercise18.8526,530500,20530,530Jun 02
Randhawa SimratEVP, Head of R&DJun 01 '26Sale90.6226,5302,404,0774,000Jun 02
Soteropoulos PaulaDirectorMay 08 '26Option Exercise8.445995,056599May 11
Soteropoulos PaulaDirectorMay 08 '26Sale85.4759951,1970May 11
Savitz RyanEVP, CFO & CBOApr 09 '26Option Exercise17.888,224147,0458,224Apr 10
Savitz RyanEVP, CFO & CBOApr 09 '26Sale89.848,224738,8440Apr 10
Savitz RyanEVP, CFO & CBOMar 31 '26Option Exercise11.74114,3671,342,857114,367Apr 01
Savitz RyanEVP, CFO & CBOMar 31 '26Sale83.00114,3679,492,5950Apr 01
Soteropoulos PaulaDirectorMar 31 '26Option Exercise8.445995,056599Apr 01
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.